美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)

25.97

0.0000

成交量：- -

成交額：- -

市值：29.25億

市盈率：-12.86

高：25.97

開：25.97

低：25.97

收：25.97

52周最高：29.99

52周最低：5.45

股本：1.13億

流通股本：1.13億

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.0190

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.newamsterdampharma.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

NewAmsterdam Pharma Company N.V.於2019年10月17日以NewAmsterdam Pharma B.V.的名義根據荷蘭法律成立為一家私人有限責任公司。NewAmsterdam Pharma於2021年10月更名為NewAmsterdam Pharma Holding B.V.。他們是一家臨床階段的生物製藥公司，為心血管疾病（CVD）高危患者開發口服非他汀類藥物，這些患者的低密度脂蛋白膽固醇（LDL-C或LDL）殘留升高，而現有療法對這些患者不夠有效或耐受良好。作為他汀類藥物的輔助藥物，一種有效的、具有成本效益的和方便的低密度脂蛋白降低療法存在着巨大的未滿足需求。他汀類藥物是目前高膽固醇高危CVD患者的標準護理。他們的主要候選產品obicetrapib是一種下一代口服低劑量膽固醇酯轉移蛋白（CETP）抑製劑，目前正在進行四項3期和2b期臨床試驗，作為單一療法和依折麥布聯合療法，用於降低LDL-C和預防主要心血管不良事件（“MACE”）。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NAMSW/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NAMSW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAMSW\",,,,,undefined,":{"symbol":"NAMSW","market":"US","secType":"STK","nameCN":"NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)","latestPrice":25.97,"timestamp":1771534800000,"preClose":25.97,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":112628458,"shares":112628458,"eps":-2.019,"marketStatus":"盤前交易","change":0,"latestTime":"02-20 05:47:05 EST","open":25.97,"high":25.97,"low":25.97,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.019,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771597800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":25.97,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAMSW\",,,,,undefined,":{"symbol":"NAMSW","floatShares":112628458,"roa":"--","roe":"--","lyrEps":0,"shares":112628458,"dividePrice":0,"high":25.97,"amplitude":0,"preClose":25.97,"low":25.97,"week52Low":5.45,"pbRate":"--","week52High":29.99,"institutionHeld":0,"latestPrice":25.97,"eps":-2.019,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.019,"open":25.97,"prevYearClose":23,"prevWeekClose":23.18,"prevMonthClose":19.45,"prevQuarterClose":23,"fiveDayClose":22.5,"twentyDayClose":22,"sixtyDayClose":28.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAMSW\",params:#limit:5,,,undefined,":[{"date":"2026-02-18","symbol":"NAMSW","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771405200000,"name":null,"time":"盤前","dateTimestamp":1771390800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAMSW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAMSW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.newamsterdampharma.com","stockEarnings":[{"period":"1week","weight":0.1542},{"period":"1month","weight":0.2818},{"period":"3month","weight":-0.0868},{"period":"6month","weight":0.8713},{"period":"1year","weight":1.9082},{"period":"ytd","weight":0.1291}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"NewAmsterdam Pharma Company N.V.於2019年10月17日以NewAmsterdam Pharma B.V.的名義根據荷蘭法律成立為一家私人有限責任公司。NewAmsterdam Pharma於2021年10月更名為NewAmsterdam Pharma Holding B.V.。他們是一家臨床階段的生物製藥公司，為心血管疾病（CVD）高危患者開發口服非他汀類藥物，這些患者的低密度脂蛋白膽固醇（LDL-C或LDL）殘留升高，而現有療法對這些患者不夠有效或耐受良好。作為他汀類藥物的輔助藥物，一種有效的、具有成本效益的和方便的低密度脂蛋白降低療法存在着巨大的未滿足需求。他汀類藥物是目前高膽固醇高危CVD患者的標準護理。他們的主要候選產品obicetrapib是一種下一代口服低劑量膽固醇酯轉移蛋白（CETP）抑製劑，目前正在進行四項3期和2b期臨床試驗，作為單一療法和依折麥布聯合療法，用於降低LDL-C和預防主要心血管不良事件（“MACE”）。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.536633},{"month":2,"riseRate":0.6,"avgChangeRate":0.089708},{"month":3,"riseRate":0.2,"avgChangeRate":-0.24039},{"month":4,"riseRate":0.8,"avgChangeRate":0.178974},{"month":5,"riseRate":0,"avgChangeRate":-0.269123},{"month":6,"riseRate":0.6,"avgChangeRate":-0.001234},{"month":7,"riseRate":0.4,"avgChangeRate":1.643099},{"month":8,"riseRate":0.6,"avgChangeRate":-0.000678},{"month":9,"riseRate":0.4,"avgChangeRate":0.030454},{"month":10,"riseRate":0.8,"avgChangeRate":0.20425},{"month":11,"riseRate":0.8,"avgChangeRate":0.092319},{"month":12,"riseRate":0.6,"avgChangeRate":0.101716}],"exchange":"NASDAQ","name":"NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)","nameEN":"NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NAMSW\",market:\"US\",,,undefined,":null}}